Machine Bio is a pre-seed radiopharma platform company enabling targeted radium therapy. Radium is a proven alpha emitter, but because of its incompatibility with therapeutically viable chelation, its reach has been limited to bone or locoregional therapies: Xofigo is FDA-approved and Alpha DaRT is in the clinic, but Xofigo only goes where calcium goes and DaRT only goes where you implant it. We are engineering archM, a protein module that captures radium without a chelator so that radium-223 and radium-224 can be delivered to antigen targets. Our model runs on two paths: partners bring targeting molecules and we give those molecules the ability to hold radium, and we develop selected programs of our own.
| Website | http://machine.bio |
| Employees | 7 (6 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research |
| Keywords | Protein Synthesis, Protein Production, Biotechnology, Dna Technology, Synthetic Biology, Biomanufacturing, Protein Engineering, Molecular Biology, Bioprocessing, Genetic Engineering, Pharmaceutical Manufacturing, Drug Discovery, Biotechnology Platform, Protein Purification, Therapeutic Proteins |
Looking for a particular Machine Bio employee's phone or email?
David Marash is the Co-Founder, CEO of Machine Bio.
6 people are employed at Machine Bio.